Ubiquitous nature of fluoroquinolones: The oscillation between antibacterial and anticancer activities

Antibiotics

Volumn 6, Issue 4, 2017, Pages

  Idowu, Temilolu ^a   Schweizer, Frank ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antibacterial; Antiproliferative; Antitumor; Fluoroquinolone; Gyrase; Immunomodulation; Topoisomerase

Indexed keywords

CIPROFLOXACIN; ENOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BACTERIAL INFECTION; BACTERIUM ADHERENCE; BIOAVAILABILITY; CELL CYCLE ARREST; CELL DIVISION; COMMUNITY ACQUIRED PNEUMONIA; DNA DAMAGE RESPONSE; DNA FRAGMENTATION; GENE EXPRESSION; GONORRHEA; HUMAN; IMMUNOMODULATION; MICROBIAL COMMUNITY; OSCILLATION; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; REVIEW;

EID: 85033460657     PISSN: None     EISSN: 20796382     Source Type: Journal    
DOI: 10.3390/antibiotics6040026     Document Type: Review

References (190)

1. Becker, B.; Cooper, M.A. Aminoglycoside antibiotics in the 21st century. ACS Chem. Biol. 2013, 8, 105–115. [CrossRef] [PubMed]
2. Cooper, M.A. A community-based approach to new antibiotic discovery. Nat. Rev. Drug Discov. 2015, 14, 587–588. [CrossRef] [PubMed]
3. Mitscher, L.A. Bacterial topoisomerase inhibitors: Quinolone and pyridone antibacterial agents. Chem. Rev. 2005, 105, 559–592. [CrossRef] [PubMed]
4. Ball, P. Quinolone generations: Natural history or natural selection? J. Antimicrob. Chemother. 2000, 46, 17–24. [CrossRef] [PubMed]
5. Aldred, K.J.; Schwanz, H.A.; Li, G.; Mcpherson, S.A.; Turnbough, C.L.; Kerns, R.J.; Osheroff, N. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug- enzyme interactions. ACS Chem. Biol. 2013, 8, 2660–2668. [CrossRef] [PubMed]
6. World Health Organization (WHO). Cancer. Available online: http://www.who.int/mediacentre/factsheets/fs297/en/ (accessed on 5 September 2017).
7. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef] [PubMed]
8. Schmitz, F.J.; Higgins, P.; Mayer, S.; Fluit, A.; Dalhoff, A. Activity of quinolones against gram-positive cocci: Mechanisms of drug action and bacterial resistance. Eur. J. Clin. Microbiol. Infect. Dis. 2002, 21, 647–659. [PubMed]
9. Drlica, K.; Zhao, X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 1997, 61, 377–392. [PubMed]
10. Baldwin, E.L.; Osheroff, N. Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents 2005, 5, 363–372. [CrossRef] [PubMed]
11. Nitiss, J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 2009, 9, 338–350. [CrossRef] [PubMed]
12. Bourikas, L.A.; Kolios, G.; Valatas, V.; Notas, G.; Drygiannakis, I.; Pelagiadis, I.; Manousou, P.; Klironomos, S.; Mouzas, I.A.; Kouroumalis, E. Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br. J. Pharmacol. 2009, 157, 362–370. [CrossRef] [PubMed]
13. Elsea, S.H.; Osheroff, N.; Nitiss, J.L. Cytotoxicity of quinolones toward eukaryotic cells. J. Biol. Chem. 1992, 267, 13150–13153. [PubMed]
14. Elsea, S.H.; Mcguirk, P.R.; Gootz, T.D.; Moynihan, M.; Osheroffl, N. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: Correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob. Agents Chemother. 1993, 37, 2179–2186. [CrossRef] [PubMed]
15. Dayam, R.; Al-Mawsawi, L.Q.; Zawahir, Z.; Witvrouw, M.; Debyser, Z.; Neamati, N. Quinolone 3-carboxylic acid pharmacophore: Design of second generation HIV-1 integrase inhibitors. J. Med. Chem. 2008, 51, 1136–1144. [CrossRef] [PubMed]
16. Stern, E.; Muccioli, G.G.; Millet, R.; Goossens, J.F.; Farce, A.; Chavatte, P.; Poupaert, J.H.; Lambert, D.M.; Depreux, P.; Hénichart, J.P. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: Synthesis, pharmacological properties and molecular modeling. J. Med. Chem. 2006, 49, 70–79. [CrossRef] [PubMed]
17. Manera, C.; Benetti, V.; Castelli, M.P.; Cavallini, T.; Lazzarotti, S.; Pibiri, F.; Saccomanni, G.; Tuccinardi, T.; Vannacci, A.; Martinelli, A.; Ferrarini, P.L. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J. Med. Chem. 2006, 49, 5947–5957. [CrossRef] [PubMed]
18. Kahnberg, P.; Howard, M.H.; Liljefors, T.; Nielsen, M.; Nielsen, E.Ø.; Sterner, O.; Pettersson, I. The use of a pharmacophore model for identification of novel ligands for the benzodiazepine binding site of the GABA A receptor. J. Mol. Graph. Model. 2004, 23, 253–261. [CrossRef] [PubMed]
19. Lager, E.; Andersson, P.; Nilsson, J.; Pettersson, I.; Nielsen, E.O.; Nielsen, M.; Sterner, O.; Liljefors, T. 4-Quinolone derivatives: High-affinity ligands at the benzodiazepine site of brain GABAA receptors. Synthesis, pharmacology, and pharmacophore modeling. J. Med. Chem. 2006, 49, 2526–2533. [CrossRef] [PubMed]
20. Park, C.H.; Lee, J.; Jung, H.Y.; Kim, M.J.; Lim, S.H.; Yeo, H.T.; Choi, E.C.; Yoon, E.J.; Kim, K.W.; Cha, J.H., et al. Identification, biological activity, and mechanism of the anti-ischemic quinolone analog. Bioorganic Med. Chem. 2007, 15, 6517–6526. [CrossRef] [PubMed]
21. Lucero, B.D.; Gomes, C.R.; Frugulhetti, I.C.; Faro, L.V.; Alvarenga, L.; De Souza, M.C.; De Souza, T.M.; Ferreira, V.F. Synthesis and anti-HSV-1 activity of quinolonic acyclovir analogues. Bioorg. Med. Chem. Lett. 2006, 16, 1010–1013. [CrossRef] [PubMed]
22. Steiner, H.; Hultmark, D.; Engström, Å.; Bennich, H.; Boman, H.G. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 1981, 292, 246–248. [CrossRef] [PubMed]
23. Ganz, T.; Selsted, M.E.; Szklarek, D.; Harwig, S.S.; Daher, K.; Bainton, D.F.; Lehrer, R.I. Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Investig. 1985, 76, 1427–1435. [CrossRef] [PubMed]
24. Zasloff, M. Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. USA 1987, 84, 5449–5453. [CrossRef] [PubMed]
25. Vandamme, D.; Landuyt, B.; Luyten, W.; Schoofs, L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol. 2012, 280, 22–35. [CrossRef] [PubMed]
26. Velkov, T.; Roberts, K.D.; Nation, R.L.; Thompson, P.E.; Li, J. Pharmacology of polymyxins: New insights into an “old” class of antibiotics. Future Microbiol. 2013, 8, 711–724. [CrossRef] [PubMed]
27. Bud, R. Penicillin: Triumph and Tragedy; Slinn, J., Ed.; Oxford University Press: Oxford, UK, 2009; ISBN 978-19-925406-4.
28. Lesher, G.Y.; Froelich, E.J.; Gruett, M.D.; Bailey, J.H.; Brundage, P.R. 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Pharm. Chem. 1962, 5, 1063–1068. [CrossRef]
29. Bisacchi, G.S. Origins of the quinolone class of antibacterials: An expanded “discovery story. J. Med. Chem. 2015, 58, 4874–4882. [CrossRef] [PubMed]
30. Domagala, J.M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 1994, 33, 685–706. [CrossRef] [PubMed]
31. Bertino, J.; Fish, D. The safety profile of the fluoroquinolones. Clin. Ther. 2000, 22, 798–817. [CrossRef]
32. Naber, K.G.; Hollauer, K.; Kirchbauer, D.; Witte, W. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections. Int. J. Antimicrob. Agents 2000, 16, 239–243. [CrossRef]
33. Stein, G.E.; Goldstein, E.J.C. Fluoroquinolones and anaerobes. Clin. Infect. Dis. 2006, 42, 1598–1607. [CrossRef] [PubMed]
34. Davis, B.D. Mechanism of bactericidal action of aminoglycosides. Microbiol. Rev. 1987, 51, 341–350. [PubMed]
35. Mingeot-Leclercq, M.P.; Glupczynski, Y.; Tulkens, P.M. Aminoglycosides: Activity and resistance. Antimicrob. Agents Chemother. 1999, 43, 727–737. [PubMed]
36. Owens, R.C.; Ambrose, P.G. Clinical use of the fluoroquinolones. Med. Clin. N. Am. 2000, 84, 1447–1469. [CrossRef]
37. Oliphant, C.M.; Green, G.M. Quinolones: A comprehensive review. Am. Fam. Physician 2002, 65, 455–464. [PubMed]
38. Hooper, D.C.; Wolfson, J.S. The Fluoroquinolones: Pharmacology, clinical uses, and toxicities in humans. Antimicrob. Agents Chemother. 1985, 28, 716–721. [CrossRef] [PubMed]
39. Freifeld, A.G.; Bow, E.J.; Sepkowitz, K.A.; Boeckh, M.J.; Ito, J.I.; Mullen, C.A.; Raad, I.I.; Rolston, K.V.; Young, J.A.H.; Wingard, J.R. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients. Clin. Infect. Dis. 2011, 52, e56–e93. [CrossRef] [PubMed]
40. Stein, G.E. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis. 1996, 23, S19–S24. [CrossRef] [PubMed]
41. Blondeau, J.M. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones’. J. Antimicrob. Chemother. 1999, 43, 1–11. [CrossRef] [PubMed]
42. Dong, Y.; Zhao, X.; Domagala, J.; Drlica, K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 1999, 43, 1756–1758. [PubMed]
43. Zhanel, G.G.; Ennis, K.; Vercaigne, L.; Walkty, A.; Gin, A.S.; Embil, J.; Smith, H.; Hoban, D.J. A critical review of the fluoroquinolones. Drugs 2002, 62, 13–59. [CrossRef] [PubMed]
44. Gorityala, B.K.; Guchhait, G.; Fernando, D.M.; Deo, S.; McKenna, S.A.; Zhanel, G.G.; Kumar, A.; Schweizer, F. Adjuvants based on hybrid antibiotics overcome resistance in Pseudomonas aeruginosa and enhance fluoroquinolone efficacy. Angew. Chem. Int. Ed. Engl. 2016, 55, 555–559. [CrossRef] [PubMed]
45. Diggle, S.P.; Matthijs, S.; Wright, V.J.; Fletcher, M.P.; Ram Chhabra, S.; Lamont, I.L.; Kong, X.; Hider, R.C.; Cornelis, P.; Cá mara, M., et al. The Pseudomonas aeruginosa 4-quinolone signal molecules HHQ and PQS play multifunctional roles in quorum sensing and iron entrapment. Chem. Biol. 2007, 14, 87–96. [CrossRef] [PubMed]
46. Zhanel, G.G.; Fontaine, S.; Adam, H.; Schurek, K.; Mayer, M.; Noreddin, A.M.; Gin, A.S.; Rubinstein, E.; Hoban, D.J. A review of new fluoroquinolones: Focus on their use in respiratory tract infections. Treat. Respir. Med. 2006, 5, 437–465. [CrossRef] [PubMed]
47. Gillespie, S.H. The role of moxifloxacin in tuberculosis therapy. Eur. Respir. Rev. 2016, 25, 19–28. [CrossRef] [PubMed]
48. Dawson, R.; Diacon, A.H.; Everitt, D.; van Niekerk, C.; Donald, P.R.; Burger, D.A.; Schall, R.; Spigelman, M.; Conradie, A.; Eisenach, K., et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: A phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015, 385, 1738–1747. [PubMed]
49. Scheld, W.M. Maintaining fluoroquinolone class efficacy: Review of influencing factors. Emerg. Infect. Dis. 2003, 9, 1–9. [CrossRef] [PubMed]
50. Pestova, E.; Millichap, J.J.; Noskin, G.A.; Peterson, L.R. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones. J. Antimicrob. Chemother. 2000, 45, 583–590. [CrossRef] [PubMed]
51. Bast, D.J.; Low, D.E.; Duncan, C.L.; Kilburn, L.; Mandell, L.A.; Davidson, R.J.; De Azavedo, J.C. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 2000, 44, 3049–3054. [CrossRef] [PubMed]
52. Smith, H.J.; Walters, M.; Hisanaga, T.; Zhanel, G.G.; Hoban, D.J. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob. Agents Chemother. 2004, 48, 3954–3958. [CrossRef] [PubMed]
53. Fukuda, H.; Kishii, R.; Takei, M.; Hosaka, M. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2001, 45, 1649–1653. [CrossRef] [PubMed]
54. Kishii, R.; Takei, M.; Fukuda, H.; Hayashi, K.; Hosaka, M. Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2003, 47, 77–81. [CrossRef] [PubMed]
55. Frémaux, A.; Sissia, G.; Geslin, P. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 1999, 43, 9–14. [CrossRef] [PubMed]
56. Goldstein, E.J.; Citron, D.M.; Merriam, C.V.; Tyrrell, K.; Warren, Y. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections. Antimicrob. Agents Chemother. 1999, 43, 1475–1479. [PubMed]
57. Poole, R.M. Nemonoxacin: First global approval. Drugs 2014, 74, 1445–1453. [CrossRef] [PubMed]
58. McKeage, K. Finafloxacin: First global approval. Drugs 2015, 75, 687–693. [CrossRef] [PubMed]
59. US FDA Highlights of Prescribing Information for Baxdela. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf (accessed on 14 September 2017).
60. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48, 1–12. [CrossRef] [PubMed]
61. Peterson, L.R. Quinolone molecular structure-activity relationships: What we have learned about improving antimicrobial activity. Clin. Infect. Dis. 2001, 33, S180–186. [CrossRef] [PubMed]
62. Shen, L.L. Molecular mechanisms of DNA gyrase inhibition by quinolone antibacterials. Adv. Pharmacol. 1994, 29, 285–304.
63. Bhanot, S.K.; Singh, M.; Chatterjee, N.R. The chemical and biological aspects of fluoroquinolones: Reality and dreams. Curr. Pharm. Des. 2001, 7, 311–335. [CrossRef] [PubMed]
64. Aldred, K.J.; McPherson, S.A.; Turnbough, C.L.; Kerns, R.J.; Osheroff, N.; Osheroff, N. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: Mechanistic basis of quinolone resistance. Nucleic Acids Res. 2013, 41, 4628–4639. [CrossRef] [PubMed]
65. Pan, X.S.; Gould, K.A.; Fisher, L.M. Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob. Agents Chemother. 2009, 53, 3822–3831. [CrossRef] [PubMed]
66. Oppegard, L.M.; Streck, K.R.; Rosen, J.D.; Schwanz, H.A.; Drlica, K.; Kerns, R.J.; Hiasa, H. Comparison of in vitro activities of fluoroquinolone-like 2,4-and 1,3-diones. Antimicrob. Agents Chemother. 2010, 54, 3011–3014. [CrossRef] [PubMed]
67. Malik, M.; Marks, K.R.; Mustaev, A.; Zhao, X.; Chavda, K.; Kerns, R.J.; Drlica, K. Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 2011, 55, 2335–2343. [CrossRef] [PubMed]
68. Al-Trawneh, S.A.; Zahra, J.A.; Kamal, M.R.; El-Abadelah, M.M.; Zani, F.; Incerti, M.; Cavazzoni, A.; Alfieri, R.R.; Petronini, P.G.; Vicini, P. Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents. Bioorg. Med. Chem. 2010, 18, 5873–5884. [CrossRef] [PubMed]
69. Anderson, V.E.; Osheroff, N. Type II topoisomerases as targets for quinolone antibacterials: Turning Dr. Jekyll into Mr. Hyde. Curr. Pharm. Des. 2001, 7, 337–353. [CrossRef] [PubMed]
70. El-Rayes, B.F.; Grignon, R.; Aslam, N.; Aranha, O.; Sarkar, F.H. Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells. Int. J. Oncol. 2002, 21, 207–211. [CrossRef] [PubMed]
71. Noris, M.D.; Madafiglio, J.; Gilbert, J.; Marshall, G.M.; Haber, M. Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin. Med. Pediatr. Oncol. 2001, 36, 177–180. [CrossRef]
72. Herold, C.; Ocker, M.; Ganslmayer, M.; Gerauer, H.; Hahn, E.G.; Schuppan, D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br. J. Cancer 2002, 86, 443–448. [CrossRef] [PubMed]
73. Hussy, P.; Maass, G.; Tümmler, B.; Grosse, F.; Schomburg, U. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob. Agents Chemother. 1986, 29, 1073–1078. [CrossRef] [PubMed]
74. Aranha, O.; Grignon, R.; Fernandes, N.; McDonnell, T.J.; Wood, D.P.; Sarkar, F.H. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int. J. Oncol. 2003, 22, 787–794. [CrossRef] [PubMed]
75. Schaeffer, A.J. The expanding role of fluoroquinolones. Am. J. Med. 2002, 113, 45S–54S. [CrossRef]
76. Simpson, K.J.; Brodie, M.J. Convulsions related to enoxacin. Lancet 1985. [CrossRef]
77. De Sarro, A.; Zappala, M.; Chimirri, A.; Grasso, S.; De Sarro, G.B. Quinolones potentiate cefazolin-induced seizures in DBA/2 mice. Antimicrob. Agents Chemother. 1993, 37, 1497–1503. [CrossRef] [PubMed]
78. Mukherjee, P.; Mandal, E.R.; Das, S.K. Evaluation of antiproliferative activity of enoxacin on a human breast cancer cell line. Int. J. Hum. Genet. 2005, 5, 57–63.
79. Melo, S.; Villanueva, A.; Moutinho, C.; Davalos, V.; Spizzo, R.; Ivan, C.; Rossi, S. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc. Natl. Acad. Sci. USA 2011, 108, 4394–4399. [CrossRef] [PubMed]
80. He, L.; Hannon, G.J. MicroRNAs: Small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5, 522–531. [CrossRef] [PubMed]
81. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834–838. [CrossRef] [PubMed]
82. Gaur, A.; Jewell, D.A.; Liang, Y.; Ridzon, D.; Moore, J.H.; Chen, C.; Ambros, V.R.; Israel, M.A. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007, 67, 2456–2468. [CrossRef] [PubMed]
83. Shan, G.; Li, Y.; Zhang, J.; Li, W.; Szulwach, K.E.; Duan, R.; Faghihi, M.A.; Khalil, A.M.; Lu, L.; Paroo, Z., et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat. Biotechnol. 2008, 26, 933–940. [CrossRef] [PubMed]
84. Patel, S.S.; Spencer, C.M. Enoxacin: A reappraisal of its clinical efficacy in the treatment of genitourinary tract infections. Drugs 1996, 51, 137–160. [CrossRef] [PubMed]
85. O’Brien, T.P.; Arshinoff, S.A.; Mah, F.S. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: Potential role of moxifloxacin. J. Cataract Refract. Surg. 2007, 33, 1790–1800. [CrossRef] [PubMed]
86. Brillault, J.; De Castro, W.V.; Harnois, T.; Kitzis, A.; Olivier, J.C.; Couet, W. P-Glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Antimicrob. Agents Chemother. 2009, 53, 1457–1462. [CrossRef] [PubMed]
87. Espiritu, C.R.G.; Caparas, V.L.; Bolinao, J.G. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J. Cataract Refract. Surg. 2007, 33, 63–68. [CrossRef] [PubMed]
88. Arshinoff, S.A.; Modabber, M. Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis. J. Cataract Refract. Surg. 2016, 42, 1730–1741. [CrossRef] [PubMed]
89. Sobolewska, B.; Hofmann, J.; Spitzer, M.S.; Bartz-Schmidt, K.U.; Szurman, P.; Yoeruek, E. Antiproliferative and cytotoxic properties of moxifloxacin on rat retinal ganglion cells. Curr. Eye Res. 2013, 38, 662–669. [CrossRef] [PubMed]
90. Matsuura, K.; Miyoshi, T.; Suto, C.; Akura, J.; Inoue, Y. Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan. J. Cart. Refract. Surg. 2013, 39, 1702–1706. [CrossRef] [PubMed]
91. Robinson, M.J.; Martin, B.A.; Gootz, T.D.; McGuirk, P.R.; Moynihan, M.; Sutcliffe, J.A.; Osheroff, N. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J. Biol. Chem. 1991, 266, 14585–14592. [PubMed]
92. Robinson, M.J.; Martin, B.A.; Gootz, T.D.; McGuirk, P.R.; Osheroff, N. Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob. Agents Chemother. 1992, 36, 751–756. [CrossRef] [PubMed]
93. Isaacs, J.T.; Pili, R.; Qian, D.Z.; Dalrymple, S.L.; Garrison, J.B.; Kyprianou, N.; Björk, A.; Olsson, A.; Leanderson, T. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006, 66, 1768–1778. [CrossRef] [PubMed]
94. Osanto, S.; van Poppel, H.; Burggraaf, J. Tasquinimod: A novel drug in advanced prostate cancer. Future Oncol. 2013, 9, 1271–1281. [CrossRef] [PubMed]
95. Mondal, E.R.; Das, S.K.; Mukherjee, P. Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture. Asian Pac. J. Cancer Prev. 2004, 5, 196–204. [PubMed]
96. Pommier, Y.; Leo, E.; Zhang, H.; Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010, 17, 421–433. [CrossRef] [PubMed]
97. Champoux, J.J. DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem. 2001, 70, 369–413. [CrossRef] [PubMed]
98. Nitiss, J.L. DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer 2009, 9, 327–337. [CrossRef] [PubMed]
99. Pommier, Y.; Sun, Y.; Huang, S.N.; Nitiss, J.L. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat. Rev. Mol. Cell Biol. 2016, 17, 703–721. [CrossRef] [PubMed]
100. Pommier, Y. Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer 2006, 6, 789–802. [CrossRef] [PubMed]
101. Pommier, Y. Drugging Topoisomerases: Lessons and Challenges. ACS Chem. Biol. 2013, 8, 82–95. [CrossRef] [PubMed]
102. Capranico, G.; Marinello, J.; Chillemi, G. Type I DNA Topoisomerases. J. Med. Chem. 2017, 60, 2169–2192. [CrossRef] [PubMed]
103. Drlica, K.; Malik, M.; Kerns, R.J.; Zhao, X. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 2008, 52, 385–392. [CrossRef] [PubMed]
104. Pan, X.S.; Fisher, L.M. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 1997, 41, 471–474. [PubMed]
105. Pan, X.S.; Fisher, L.M. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 1998, 42, 2810–2816. [PubMed]
106. Fournier, B.; Zhao, X.; Lu, T.; Drlica, K.; Hooper, D.C. Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: Different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob. Agents Chemother. 2000, 44, 2160–2165. [CrossRef] [PubMed]
107. Kreuzer, K.N.; Cozzarelli, N.R. Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: Effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J. Bacteriol. 1979, 140, 424–435. [PubMed]
108. Arnoldi, E.; Pan, X.S.; Fisher, L.M. Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases. Nucleic Acids Res. 2013. [CrossRef] [PubMed]
109. Laponogov, I.; Veselkov, D.A.; Crevel, I.M.T.; Pan, X.S.; Fisher, L.M.; Sanderson, M.R. Structure of an “open” clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport. Nucleic Acids Res. 2013, 41, 9911–9923. [CrossRef] [PubMed]
110. Laponogov, I.; Sohi, M.K.; Veselkov, D.A.; Pan, X.S.; Sawhney, R.; Thompson, A.W.; McAuley, K.E.; Fisher, L.M.; Sanderson, M.R. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat. Struct. Mol. Biol. 2009, 16, 667–669. [CrossRef] [PubMed]
111. Vos, S.M.; Tretter, E.M.; Schmidt, B.H.; Berger, J.M. All tangled up: How cells direct, manage and exploit topoisomerase function. Nat. Rev. Mol. Cell Biol. 2011, 12, 827–841. [CrossRef] [PubMed]
112. Wohlkonig, A.; Chan, P.F.; Fosberry, A.P.; Homes, P.; Huang, J.; Kranz, M.; Leydon, V.R.; Miles, T.J.; Pearson, N.D.; Perera, R.L., et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat. Struct. Mol. Biol. 2010, 17, 1152–1153. [CrossRef] [PubMed]
113. Shen, L.L.; Pernet, A.G. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: The target of the drugs is DNA. Proc. Natl. Acad. Sci. USA 1985, 82, 307–311. [CrossRef] [PubMed]
114. Palù, G.; Valisena, S.; Ciarrocchi, G.; Gatto, B.; Palumbo, M. Quinolone binding to DNA is mediated by magnesium ions. Proc. Natl. Acad. Sci. USA 1992, 89, 9671–9675. [CrossRef] [PubMed]
115. Shen, L.L.; Mitscher, L.A.; Sharma, P.N.; O’Donnell, T.J.; Chu, D.W.; Cooper, C.S.; Rosen, T.; Pernet, A.G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: A cooperative drug-DNA binding model. Biochemistry 1989, 28, 3886–3894. [CrossRef] [PubMed]
116. Shen, L.L.; Baranowski, J.; Pernet, A.G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: Specificity and cooperativity of drug binding to DNA. Biochemistry 1989, 28, 3879–3885. [CrossRef] [PubMed]
117. Shen, L.L.; Kohlbrenner, W.E.; Weigl, D.; Baranowski, J. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J. Biol. Chem. 1989, 264, 2973–2978. [PubMed]
118. Yoshida, H.; Bogaki, M.; Nakamura, M.; Yamanaka, L.M.; Nakamura, S. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 1991, 35, 1647–1650. [CrossRef] [PubMed]
119. Blower, T.R.; Williamson, B.H.; Kerns, R.J.; Berger, J.M. Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA. 2016, 113, 1706–1713. [CrossRef] [PubMed]
120. Leo, E.; Gould, K.A.; Pan, X.S.; Capranico, G.; Sanderson, M.R.; Palumbo, M.; Fisher, L.M. Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site. J. Biol. Chem. 2005, 280, 14252–14263. [CrossRef] [PubMed]
121. Kwok, Y.; Zeng, Q.; Hurley, L.H. Structural insight into a quinolone-topoisomerase II-DNA complex. Further evidence for a 2:2 quinobenzoxazine-mg2+ self-assembly model formed in the presence of topoisomerase II. J. Biol. Chem. 1999, 274, 17226–17235. [CrossRef] [PubMed]
122. Kathiravan, M.K.; Khilare, M.M.; Nikoomanesh, K.; Chothe, A.S.; Jain, K.S. Topoisomerase as target for antibacterial and anticancer drug discovery. J. Enzyme Inhib. Med. Chem. 2013, 28, 419–435. [CrossRef] [PubMed]
123. Tewey, K.M.; Rowe, T.C.; Yang, L.; Halligan, B.D.; Liu, L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984, 226, 466–468. [CrossRef] [PubMed]
124. Liu, L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 1989, 58, 351–375. [CrossRef] [PubMed]
125. Walker, J.V.; Nitiss, J.L. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Investig. 2002, 20, 570–589. [CrossRef]
126. Goto, T.; Wang, J.C. Yeast DNA topoisomerase II is encoded by a single-copy, essential gene. Cell 1984, 36, 1073–1080. [CrossRef]
127. Wyckoff, E.; Natalie, D.; Nolan, J.M.; Lee, M.; Hsieh, T. Structure of the Drosophila DNA topoisomerase II gene. Nucleotide sequence and homology among topoisomerases II. J. Mol. Biol. 1989, 205, 1–13. [CrossRef]
128. Nitiss, J.L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta Gene Struct. Expr. 1998, 1400, 63–81. [CrossRef]
129. Yang, X.; Li, W.; Prescott, E.D.; Burden, S.J.; Wang, J.C. DNA topoisomerase IIβ and neural development. Science 2000, 287, 131–134. [CrossRef] [PubMed]
130. Wang, J.C. Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 3, 430–440. [CrossRef] [PubMed]
131. Mandell, G.L.; Coleman, E. Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob. Agents Chemother. 2001, 45, 1794–1798. [CrossRef] [PubMed]
132. Carryn, S.; Van Bambeke, F.; Mingeot-Leclercq, M.P.; Tulkens, P.M. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob. Agents Chemother. 2002, 46, 2095–2103. [CrossRef] [PubMed]
133. McClendon, A.K.; Rodriguez, A.C.; Osheroff, N. Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: Implications for enzyme action ahead of replication forks. J. Biol. Chem. 2005, 280, 39337–39345. [CrossRef] [PubMed]
134. D’arpa, P.; Beardmore, C.; Liu, L.F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 1990, 50, 6919–6924. [PubMed]
135. Andoh, T.; Ishida, R. Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta 1998, 1400, 155–171. [CrossRef]
136. Hsiung, Y.; Elsea, S.H.; Osheroff, N.; Nitiss, J.L. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. J. Biol. Chem. 1995, 270, 20359–20364. [CrossRef] [PubMed]
137. Gruger, T.; Nitiss, J.L.; Maxwell, A.; Zechiedrich, E.L.; Heisig, P.; Seeber, S.; Pommier, Y.; Strumberg, D. A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II. Antimicrob. Agents Chemother. 2004, 48, 4495–4504. [CrossRef] [PubMed]
138. Gabrielli, B.; Brooks, K.; Pavey, S. Defective cell cycle checkpoints as targets for anti-cancer therapies. Front. Pharmacol. 2012. [CrossRef] [PubMed]
139. Schaad, U.B. Will fluoroquinolones ever be recommended for common infections in children? Pediatr. Infect. Dis. J. 2007, 26, 865–867. [CrossRef] [PubMed]
140. Kohlbrenner, W.E.; Wideburg, N.; Weigl, D.; Saldivar, A.; Chu, D.T. Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282. Antimicrob. Agents Chemother. 1992, 36, 81–86. [CrossRef] [PubMed]
141. Permana, P.A.; Snapka, R.M.; Shen, L.L.; Chu, D.T.; Clement, J.J.; Plattner, J.J. Quinobenoxazines: A class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry 1994, 33, 11333–11339. [CrossRef] [PubMed]
142. Tomita, K.; Tsuzuki, Y.; Shibamori, K.; Tashima, M.; Kajikawa, F.; Sato, Y. Synthesis and structure-activity relationships of novel 7-substituted antitumor agents. Part 1. J. Med. Chem. 2002, 45, 5564–5575. [CrossRef] [PubMed]
143. Tsuzuki, Y.; Tomita, K.; Shibamori, K.I.; Sato, Y.; Kashimoto, S.; Chiba, K. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. J. Med. Chem. 2004, 47, 2097–2109. [CrossRef] [PubMed]
144. Golub, A.G.; Yakovenko, O.Y.; Bdzhola, V.G.; Sapelkin, V.M.; Zien, P.; Yarmoluk, S.M. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J. Med. Chem. 2006, 49, 6443–6450. [CrossRef] [PubMed]
145. Meggio, F.; Pinna, L.A. One-thousand-and-one substrates of protein kinase CK2? FASEB 2003, 17, 349–368. [CrossRef] [PubMed]
146. Tauber, S.C.; Nau, R. Immunomodulatory properties of antibiotics. Curr. Mol. Pharmacol. 2008, 1, 68–79. [PubMed]
147. Kanoh, S.; Rubin, B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 2010, 23, 590–615. [CrossRef] [PubMed]
148. Guchhait, G.; Altieri, A.; Gorityala, B.; Yang, X.; Findlay, B.; Zhanel, G.G.; Mookherjee, N.; Schweizer, F. Amphiphilic tobramycins with immunomodulatory properties. Angew. Chem. Int. Ed. Engl. 2015, 54, 6278–6282. [CrossRef] [PubMed]
149. Roche, Y.; Fay, M.; Gougerot-Pocidalo, M.A. Effects of quinolones on interleukin 1 production in vitro by human monocytes. Immunopharmacology 1987, 13, 99–109. [CrossRef]
150. Riesbeck, K.; Andersson, J.; Gullberg, M.; Forsgren, A. Fluorinated 4-quinolones induce hyperproduction of interleukin 2. Proc. Natl. Acad. Sci. USA 1989, 86, 2809–2813. [CrossRef] [PubMed]
151. Riesbeck, K. Immunomodulating activity of quinolones: Review. J. Chemother. 2002, 14, 3–12. [CrossRef] [PubMed]
152. Dalhoff, A.; Shalit, I. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 2003, 3, 359–371. [CrossRef]
153. Nau, R.; Eiffert, H. Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis. Clin. Microbiol. Rev. 2002, 15, 95–110. [CrossRef] [PubMed]
154. Nau, R.; Eiffert, H. Minimizing the release of proinflammatory and toxic bacterial products within the host: A promising approach to improve outcome in life-threatening infections. FEMS Immunol. Med. Microbiol. 2005, 44, 1–16. [CrossRef] [PubMed]
155. Turner, M.D.; Nedjai, B.; Hurst, T.; Pennington, D.J. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim. Biophys. Acta Mol. Cell Res. 2014, 1843, 2563–2582. [CrossRef] [PubMed]
156. Baggiolini, M. Chemokines and leukocyte traffic. Nature 1998, 392, 565–568. [CrossRef] [PubMed]
157. Laing, K.J.; Secombes, C.J. Chemokines. Dev. Comp. Immunol. 2004, 28, 443–460. [CrossRef] [PubMed]
158. Nitsche, D.; Schulze, C.; Oesser, S.; Dalhoff, A.; Sack, M. Impact of different classes of antimicrobial agents on plasma endotoxin activity. Arch. Surg. 1996. [CrossRef]
159. Gollapudi, S.V.; Chuah, S.K.; Harvey, T.; Thadepalli, H.D.; Thadepalli, H. In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis. Antimicrob. Agents Chemother. 1993, 37, 1711–1712. [CrossRef] [PubMed]
160. Thadepalli, H.; Gollapudi, S.V.; Chuah, S.K. Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess. Antimicrob. Agents Chemother. 1986, 30, 574–576. [CrossRef] [PubMed]
161. Thadepalli, H.; Hajji, M.; Perumal, V.K.; Chuah, S.K.; Gollapudi, S. Evaluation of temafloxacin in a rat model of intra-abdominal abscess. J. Antimicrob. Chemother. 1992, 29, 687–692. [CrossRef] [PubMed]
162. Thadepalli, H.; Reddy, U.; Chuah, S.K.; Thadepalli, F.; Malilay, C.; Polzer, R.J.; Hanna, N.; Esfandiari, A.; Brown, P.; Gollapudi, S. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob. Agents Chemother. 1997, 41, 583–586. [PubMed]
163. Thadepalli, H.; Chuah, S.K.; Reddy, U.; Hanna, N.; Clark, R.; Polzer, R.J.; Gollapudi, S. Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice. Antimicrob. Agents Chemother. 1997, 41, 1933–1936. [PubMed]
164. King, A.; May, J.; French, G.; Phillips, I. Comparative in vitro activity of gemifloxacin. J. Antimicrob. Chemother. 2000, 45, 1–12. [CrossRef] [PubMed]
165. Riesbeck, K.; Sigvardsson, M.; Leanderson, T.; Forsgren, A. Superinduction of cytokine gene transcription by ciprofloxacin. J. Immunol. 1994, 153, 343–352. [PubMed]
166. Riesbeck, K.; Forsgren, A. Commentary on ciprofloxacin-dependent superinduction of IL-2 synthesis and thymidine uptake. Transplantation 1998, 1282–1283.
167. Abdel-Aziz, M.; Park, S.E.; Abuo-Rahma, G.D.; Sayed, M.A.; Kwon, Y. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: Synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity. Eur. J. Med. Chem. 2013, 69, 427–438. [CrossRef] [PubMed]
168. Idowu, T.; Samadder, P.; Arthur, G.; Schweizer, F.M. Amphiphilic modulation of glycosylated antitumor ether lipids results in a potent triamino scaffold against epithelial cancer cell lines and BT474 cancer stem cells. J. Med. Chem. 2017. [CrossRef] [PubMed]
169. Idowu, T.; Samadder, P.; Arthur, G.; Schweizer, F. Design, synthesis and antitumor properties of glycosylated antitumor ether lipid (GAEL)-chlorambucil-hybrids. Chem. Phys. Lipids 2016, 194, 139–148. [CrossRef] [PubMed]
170. Ogunsina, M.; Samadder, P.; Idowu, T.; Arthur, G.; Schweizer, F. Replacing D-glucosamine with Its L-enantiomer in glycosylated antitumor ether lipids (GAELs) retains cytotoxic effects against epithelial cancer cells and cancer stem cells. J. Med. Chem. 2017, 60, 2142–2147. [CrossRef] [PubMed]
171. Silva, H.; Valério Barra, C.; França da Costa, C.; de Almeida, M.V.; César, E.T.; Silveira, J.N.; Garnier-Suillerot, A.; Silva de Paula, F.C.; Pereira-Maia, E.C.; Fontes, A.P.S. Impact of the carbon chain length of novel platinum complexes derived from N-alkyl-propanediamines on their cytotoxic activity and cellular uptake. J. Inorg. Biochem. 2008, 102, 767–772. [CrossRef] [PubMed]
172. Sánchez-Martín, R.; Campos, J.M.; Conejo-García, A.; Cruz-López, O.; Báñez-Coronel, M.; Rodríguez-González, A.; Gallo, M.A.; Lacal, J.C.; Espinosa, A. Symmetrical bis-quinolinium compounds: New human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line. J. Med. Chem. 2005, 48, 3354–3363. [CrossRef] [PubMed]
173. Teicher, B.A. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem. Pharmacol. 2008, 75, 1262–1271. [CrossRef] [PubMed]
174. Carew, J.S.; Giles, F.J.; Nawrocki, S.T. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008, 269, 7–17. [CrossRef] [PubMed]
175. Azéma, J.; Guidetti, B.; Dewelle, J.; Le Calve, B.; Mijatovic, T.; Korolyov, A.; Vaysse, J.; Malet-Martino, M.; Martino, R.; Kiss, R. 7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: Synthesis and in vitro biological evaluation as potential antitumor agents. Bioorg. Med. Chem. 2009, 17, 5396–5407. [CrossRef] [PubMed]
176. Shalit, I.; Kletter, Y.; Weiss, K.; Gruss, T.; Fabian, I. Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones. Eur. J. Haematol. 2009, 58, 92–98. [CrossRef]
177. Shi, Y.; Liu, C.H.; Roberts, A.I.; Das, J.; Xu, G.; Ren, G.; Zhang, Y.; Zhang, L.; Yuan, Z.R.; Tan, H.S.W.; Das, G.; Devadas, S. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: What we do and don’t know. Cell Res. 2006, 16, 126–133. [CrossRef] [PubMed]
178. Ball, P.; Mandell, L.; Niki, Y.; Tillotson, G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 1999, 21, 407–421. [CrossRef] [PubMed]
179. Blum, M.D.; Graham, D.J.; McCloskey, C.A. Temafloxacin syndrome: Review of 95 cases. Clin. Infect. Dis. 1994, 18, 946–950. [CrossRef] [PubMed]
180. Stahlmann, R. Clinical toxicological aspects of fluoroquinolones. Toxicol. Lett. 2002, 127, 269–277. [CrossRef]
181. Ball, P. Quinolone-induced QT interval prolongation: A not-so-unexpected class effect. J. Antimicrob. Chemother. 2000, 45, 557–559. [CrossRef] [PubMed]
182. Uivarosi, V. Metal complexes of quinolone antibiotics and their applications: An update. Molecules 2013, 18, 11153–11197. [CrossRef] [PubMed]
183. Turel, I. The interactions of metal ions with quinolone antibacterial agents. Coord. Chem. Rev. 2002, 232, 27–47. [CrossRef]
184. Shimada, J.; Shiba, K.; Oguma, T.; Miwa, H.; Yoshimura, Y.; Nishikawa, T.; Okabayashi, Y.; Kitagawa, T.; Yamamoto, S. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob. Agents Chemother. 1992, 36, 1219–1224. [CrossRef] [PubMed]
185. Owens, R.C.; Ambrose, P.G. Antimicrobial safety: Focus on fluoroquinolones. Clin. Infect. Dis. 2005, 41, S144–S157. [CrossRef] [PubMed]
186. Redgrave, L.S.; Sutton, S.B.; Webber, M.A.; Piddock, L.J.V. Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014, 22, 438–445. [CrossRef] [PubMed]
187. Crozat, E.; Philippe, N.; Lenski, R.E.; Geiselmann, J.; Schneider, D. Long-term experimental evolution in Escherichia coli. XII. DNA topology as a key target of selection. Genetics 2005, 169, 523–532. [CrossRef] [PubMed]
188. Riesbeck, K.; Gullberg, M.; Forsgren, A. Evidence that the antibiotic ciprofloxacin counteracts cyclosporine-dependent suppression of cytokine production. Transplantation 1994, 57, 267–272. [CrossRef] [PubMed]
189. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3–26. [CrossRef]
190. O’Shea, R.; Moser, H.E. Physicochemical properties of antibacterial compounds: Implications for drug discovery. J. Med. Chem. 2008, 51, 2871–2878. [CrossRef] [PubMed]